Software
Monkeypox virus nucleic acid detection kits and ELISA kits
As the leading custom service provider, Creative Biolabs has been keeping a close eye on the development of the epidemic situation and accelerating the development of detection kits. Creative Biolabs provides Monkeypox virus nucleic acid detection kits and ELISA kits. Please feel free to contact us to learn more products and custom production.
Vaccine-Based Anti-monkeypox Drug Discovery Solutions
As a professional pre-clinical vaccine development and production server, Creative Biolabs has been engaged in the vaccine industry for over a decade. We combine traditional and updated technologies to help our global customers to design vaccine-based anti-monkeypox drug discovery solutions that address the urgent need for unmet treatment for monkeypox.
Monkeypox virus antibody
Creative Biolabs is the leading custom service provider that has extensive experience in various antibody production and engineering fields. As the leading custom service provider specializing in antibody production and engineering fields, Creative Biolabs has been keeping a close eye on the development of the epidemic situation and accelerating the development of monkeypox antibodies. Please feel free to contact us to learn more products and custom production.
engineering macrophage membrane
Macrophage membrane coated nanoparticles (NPs) exhibit a thin layer on the surface, a slightly larger size, and a negatively charged surface zeta potential and contain membrane proteins derived from macrophages. Macrophage membrane-mediated drug delivery systems are being paid more and more attention. Research scientists at Creative Biolabs are experts in engineering macrophage membrane as drug carriers and are happy to assist clients based on their requirements. Creative Biolabs provides efficiencies with shorter timelines to accelerate our clients' project development.
macrophage marker development
Classically (M1) and alternatively activated (M2) macrophages exhibit distinct functions. In vivo, there is a spectrum of macrophage phenotypes exists, and in vitro, there is low or non-selective M2 marker protein expression. Therefore, by leveraging the wealth of knowledge that we have on macrophage marker development, Creative Biolabs performs the most comprehensive analysis of the transcriptional signature of M1 and M2 macrophages in humans and mice. Our strategy can identify M1-exclusive or M2-exclusive markers, which can be used to distinguish between M1 and M2 macrophages. Our skilled scientists provide efficiencies with shorter timelines to accelerate our clients' M1/M2 macrophage marker development projects.
M1 macrophage polarization assay
Macrophage Therapeutics Development Platform at Creative Biolabs can generate macrophages by treating isolated bone marrow-derived or peritoneal macrophages with specific stimuli, including secreting inflammatory cytokines, such as tumor necrosis factor–α (TNF-α), interferon-gamma (IFN-γ), and interleukins (IL-1, IL-6, IL-8), and bacterial components such as lipopolysaccharide (LPS), growth factors including granulocyte-macrophage colony-stimulating factor (GM-CSF), or matrix metalloproteinases (MMPs). Moreover, based on surface markers and the distinctly produced cytokines, we also provide the validation of each polarized macrophage. Enzyme-linked immunosorbent assay (ELISA), immunohistochemistry (IHC), flow cytometry (FC) could be conducted to analyze surface markers and cytokines expression upon request. Our polarization protocols are designed to achieve a stable, optimal, and effective regimen for in vitro induction to drive antigen-specific immune responses. Our M1 macrophage polarization assay allows the assessment of cytokine profiles, cell surface receptor expression, scavenging functions, and the ability to activate or suppress T-cell proliferation.
macrophage characterization
With an experienced team of in-house human and mouse macrophage characterization experts, Creative Biolabs has explored a comprehensive portfolio of strategies to provide our clients with highly customizable solutions. From project design to result analysis, our seasoned scientists will work with you to develop a complete solution for our client's needs in macrophage characterization.
Lectin Pathway
The lectin pathway is initiated when one of the pattern recognition receptors (PRRs) binds to pathogen-associated molecular patterns (PAMPs) (D-mannose, N-acetyl-D-glucosamine, or acetyl groups), on the surface of invading microorganisms or apoptotic/necrotic cells. The well-characterized PRRs include mannose-binding lectin (MBL), ficolins and collagen-containing soluble C-type lectins (collectins), such as kidney collectin-11 (CL-K1). These circulated lectins are complexed with serine proteases named MBL-associated serine proteases (MASPs), comprising MASP-1, -2, and -3. The enzymatic cascade is really started after the binding of MBL/MASPs, CL-K1/MASPs, or ficolin/MASPs complexes to their targets.
complement hemolysis
With the deepening of research and the development of complement therapeutics, a variety of complement inhibitors, such as CD55, CD59, anti-C5 antibody, C1 inhibitor, have been approved and developed for human disease treatment. This requires a method to evaluate the inhibitory activity of these inhibitors, namely complement hemolysis inhibition assay. The inhibition activities can be determined by comparison of the hemolysis inhibition between normal complement samples with that of complement samples with inhibitors. Two references can be used as a measure of the activity of complement inhibition, one is the value of CH50 or AH50, the other is the hemolysis inhibition curve of complement samples with gradient dilution.
CD59 complement
As an important target for therapeutic antibody exploration and clinical trial, CD59 complement has become the global research hotspot, due to the importance in the regulation of complement activation. With advanced technologies and long-term scientific expertise, Creative Biolabs has successfully developed a series of innovative and effective therapeutic antibodies for related diseases. Now, we are proud to offer a full range of formulation development services for complement drug discovery.